A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational

Trial Details

NCT ID
NCT07749586
Phase
PHASE1 / PHASE2
Sponsor
Arvinas Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • ARV-6723
  • Pembrolizumab
  • SOC
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Part A1 dose escalation and A2 dose optimization: Participants must meet all of the following criteria:
  • Have a histologic or cytologic diagnosis of unresectable or metastatic solid tumor malignancy.
  • Have previously received at least one prior therapy targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic …
  • Have received prior SOC therapy appropriate for their disease type and stage and have no remaining available treatment options with established cli…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →